

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
26 April 2001 (26.04.2001)

PCT

(10) International Publication Number
WO 01/28567 A2(51) International Patent Classification⁷: A61K 31/662,
A61P 19/08

(21) International Application Number: PCT/US00/28713

(22) International Filing Date: 17 October 2000 (17.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/160,019 18 October 1999 (18.10.1999) US(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, YU, ZA, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (*for all designated States except US*): THE
DOW CHEMICAL COMPANY [US/US]; 2030 Dow
Center, Midland, MI 48674 (US).**Published:**— Without international search report and to be republished
upon receipt of that report.

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): FRANK, R. Keith
[US/US]; 213 Pansy Path, Lake Jackson, TX 77566 (US).*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*(74) Agent: KARADZIC, Dragan, J.; Intellectual Property,
B-1211, 2301 N. Brazosport Boulevard, Freeport, TX
77541 (US).

WO 01/28567 A2

(54) Title: AMINOALKYLENEPHOSPHONATES FOR TREATMENT OF BONE DISORDERS

(57) Abstract: A method for preventing or minimizing loss of bone mineral in mammals which method comprises administering to a mammal an amount of an aminoalkylenephosphonate which is effective to prevent or minimize loss of bone mineral density. The aminoalkylenephosphonates of the present invention should have at least one R-N(Alk-PO₃H₂)₂ group or at least two RRN-Alk-PO₃H₂ groups wherein R and R can be, same or different, aliphatic or cyclic moiety, and Alk is an alkylene group having from 1 to 4 carbon atoms.